ATHEROGENICS LOSS WIDENS

AtheroGenics Inc. went deeper in the red in 2005 as its research and development costs jumped 20.4 percent. The Atlanta-based drug developer had a net loss of $82.6 million and a loss per share of $2.19, compared with a net loss of $69.6 million and a loss per share of $1.88 in 2004. The company had no revenue in either period.

Atlanta Business Journal (http://atlanta.bizjournals.com/atlanta/stories/2006/02/27/daily9.html)